Indications for Balloon Mitral Valvuloplasty in Severe Mitral Stenosis
Balloon mitral valvuloplasty (BMV) is recommended as first-line treatment for symptomatic patients with severe mitral stenosis (MVA ≤1.5 cm²) who have favorable valve morphology, no left atrial thrombus, and less than moderate mitral regurgitation. 1, 2
Primary Class I Indications (Strongest Evidence)
Symptomatic Severe MS with Favorable Anatomy
- NYHA Class II-IV symptoms
- MVA ≤1.5 cm² (Stage D)
- Favorable valve morphology (typically Wilkins score ≤8)
- Absence of left atrial thrombus (must be excluded by TEE)
- Less than moderate mitral regurgitation
- Level of Evidence: A 1, 2
This represents the gold standard indication, supported by multiple randomized controlled trials demonstrating comparable outcomes to surgical commissurotomy with lower morbidity 3.
Class IIa Indications (Reasonable to Perform)
Asymptomatic Very Severe MS
- MVA ≤1.0 cm² (Stage C)
- Favorable valve morphology
- No contraindications
- Consider when there is high thromboembolic risk or new pulmonary artery systolic pressure ≥50 mmHg 1, 2
Suboptimal Anatomy but Low-Risk Features
BMV should be considered as initial treatment even with suboptimal anatomy (Wilkins score >8) if the patient lacks unfavorable clinical characteristics and is at high surgical risk 1.
Class IIb Indications (May Be Considered)
New-Onset Atrial Fibrillation
- MVA ≤1.5 cm²
- New onset AF
- Favorable morphology
- Rationale: Lowering left atrial pressure may facilitate rhythm control and reduce thromboembolic risk 2
Hemodynamically Significant MS with Larger Valve Area
- MVA 1.5-2.0 cm²
- Exercise transmitral gradient >15 mmHg OR
- Exercise pulmonary artery systolic pressure >60 mmHg
- This addresses patients with genuine symptoms despite "moderate" valve area measurements 1, 2
High-Risk Surgical Candidates with Suboptimal Anatomy
- NYHA Class III-IV symptoms
- MVA ≤1.5 cm²
- Suboptimal valve anatomy (Wilkins score >8 or commissural calcification)
- Not surgical candidates or prohibitive surgical risk
- Important caveat: Success rates are lower (42% optimal outcome with Wilkins >8), but may still benefit severely symptomatic patients without alternatives 2
Absolute Contraindications
- Moderate-to-severe or severe mitral regurgitation (≥3+)
- Left atrial or left atrial appendage thrombus (must exclude with TEE)
- Severe or bicommissural calcification
- Concomitant severe aortic valve disease requiring surgery
- Severe subvalvular disease with leaflet tethering
Key Anatomical Assessment Requirements
Favorable Morphology Criteria
- Wilkins echocardiographic score ≤8 (assesses leaflet mobility, thickening, calcification, and subvalvular apparatus)
- Pliable, non-calcified leaflets
- Commissural fusion as predominant mechanism
- Minimal subvalvular fibrosis
Pre-Procedure Mandatory Evaluation
- Transesophageal echocardiography to exclude left atrial thrombus
- Assessment of mitral regurgitation severity
- Evaluation of valve morphology and calcium distribution
- Measurement of pulmonary artery pressures
Clinical Pearls and Pitfalls
Common Pitfall: Assuming all patients with MVA >1.5 cm² don't need intervention. Patients with large body surface area, high cardiac output states, or elevated pulmonary vascular resistance may be genuinely symptomatic with MVA 1.5-2.0 cm² and benefit from BMV if exercise hemodynamics confirm significant gradients 2.
Critical Success Factor: BMV should be performed at comprehensive valve centers by experienced operators with immediate surgical backup available. Operator experience significantly impacts outcomes and complication rates 2.
Restenosis Consideration: If restenosis occurs after prior BMV and is due to commissural refusion (rather than progressive calcification), repeat BMV can be performed with reasonable success 1.
Expected Outcomes
When performed in appropriate candidates with favorable anatomy:
- Immediate increase in MVA from ~0.9 cm² to 2.0-2.4 cm²
- Sustained improvement maintained at 3 years
- Low complication rates: mortality 0-0.5%, stroke 1-2%, severe MR requiring surgery 1.6-3%
- Restenosis rates: 4-31% depending on follow-up duration and valve morphology 3, 4
Patients with favorable morphology have significantly better long-term outcomes, with 10-year event-free survival of 88-92% compared to those with unfavorable anatomy 4.